August 7, 2013 — A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma (DLBCL) — a key factor in tailoring patient management plans — has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine. Imaging with 18F-FDG positron emission tomography/computed tomography (PET/CT), when compared to bone marrow biopsy, was more sensitive, showed a higher negative predictive value and was more accurate, changing treatment for 42 percent of patients with bone marrow involvement.

DLBCL is the most frequent subtype of high-grade non-Hodgkin lymphoma, accounting for nearly 30 percent of all newly diagnosed cases in the United States. In recent decades, there has been a 150 percent increase in incidence of DLBCL.

“In our study, we showed that in diffuse large B-cell lymphoma, 18F-FDG PET/CT has better diagnostic performance than bone marrow biopsy to detect bone marrow involvement and provides a better prognostic stratification. While bone marrow biopsy is considered the gold standard to evaluate bone marrow involvement by high-grade lymphomas, 18F-FDG PET/CT is in fact the best method to evaluate extension of the disease, as well as avoid invasive procedures,” said Louis Berthet, M.D., lead author of the study, “In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Dose Biopsy.”

The retrospective study included 133 patients diagnosed with DLBCL. All patients received both a whole-body 18F-FDG PET/CT scan, as well as a bone marrow biopsy to determine bone marrow involvement. A final diagnosis of bone marrow involvement was made if the biopsy was positive, or if the positive PET/CT scan was confirmed by a guided biopsy, by targeted magnetic resonance imaging (MRI) or, after chemotherapy, by the concomitant disappearance of focal bone marrow uptake and uptake in other lymphoma lesions on 18F-FDG PET/CT reassessment. Progression-free survival and overall survival were then analyzed.

Thirty-three patients were considered to have bone marrow involvement. Of these, eight were positive according to the biopsy and 32 were positive according to the PET/CT scan. 18FDG PET/CT was more sensitive (94 percent vs. 24 percent), showed a higher negative predictive value (98 percent vs. 80 percent) and was more accurate (98 percent vs. 81 percent) than bone marrow biopsy. Among the 26 patients with positive 18F-FDG PET/CT results and negative biopsy results, 11 were upstaged to stage IV by PET/CT, which changed their treatment plans. 18F-FDG PET/CT was also determined to be an independent predictor of progression-free survival.

“Our findings add to the literature to prove the significance of 18F-FDG PET/CT in cancer evaluation and to democratize this imaging method,” said Berthet.

“Molecular imaging is the best method to adapt targeted therapies to each patient. The emergence of PET/MRI and novel radiotracers predicts an exciting new future for our field.”

Authors of the article, “In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Dose Biopsy,” include Louis Berthet, Salim Kanoun, Alina Berriolo-Riedinger, Michael Toubeau and Inna Dygai-Cochet, Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France; Alexandre Cochet, Olivier Humbert and François Brunotte, Department of Nuclear Medicine, Centre Georges-François Leclerc, Dijon, France, and Le21 UMR CNRS 5158, Dijon, France; and Caroline Legouge and Olivier Casasnovas, Department of Clinical Hematology, Centre Hospitalier Régional Universitaire, Hôspital Le Bocage, Dijon, France.

For more information: jnm.snmjournals.org


Related Content

News | Radiopharmaceuticals and Tracers

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
Feature | Radiology Business

Here is a recap of what ITN viewers found most interesting during the month of September: 1. Lasting Lung Damage Seen in ...

Time October 03, 2022
arrow
News | Radiopharmaceuticals and Tracers

September 22, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 22, 2022
arrow
Feature | Contrast Media | By Christine Book

The theme “Everyday progress” seems appropriate for the imaging community in 2022. What a year it’s been. Supply ...

Time September 14, 2022
arrow
News | SPECT-CT

September 7, 2022 — The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to ...

Time September 07, 2022
arrow
News | Radiopharmaceuticals and Tracers

August 26, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 25, 2022
arrow
News | Proton Therapy

August 19, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time August 19, 2022
arrow
News | SNMMI

August 16, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of the Patient ...

Time August 16, 2022
arrow
Feature | Magnetic Resonance Imaging (MRI) | Christine Book

August 10, 2022 — The imaging community has lost a legend, recognized for having revolutionized the field of diagnostic ...

Time August 10, 2022
arrow
News | PET Imaging

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
Subscribe Now